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Abstract
Individuals of the same chronological age exhibit disparate rates of biological ageing. Consequently, a number of
methodologies have been proposed to determine biological age and primarily exploit variation at the level of DNA
methylation (DNAm). A novel epigenetic clock, termed ‘DNAm GrimAge’ has outperformed its predecessors in predicting
the risk of mortality as well as many age-related morbidities. However, the association between DNAm GrimAge and
cognitive or neuroimaging phenotypes remains unknown. We explore these associations in the Lothian Birth Cohort 1936
(n= 709, mean age 73 years). Higher DNAm GrimAge was strongly associated with all-cause mortality over the eighth
decade (Hazard Ratio per standard deviation increase in GrimAge: 1.81, P < 2.0 × 10−16). Higher DNAm GrimAge was
associated with lower age 11 IQ (β=−0.11), lower age 73 general cognitive ability (β=−0.18), decreased brain volume
(β=−0.25) and increased brain white matter hyperintensities (β= 0.17). There was tentative evidence for a longitudinal
association between DNAm GrimAge and cognitive decline from age 70 to 79. Sixty-nine of 137 health- and brain-related
phenotypes tested were significantly associated with GrimAge. Adjusting all models for childhood intelligence attenuated to
non-significance a small number of associations (12/69 associations; 6 of which were cognitive traits), but not the association
with general cognitive ability (33.9% attenuation). Higher DNAm GrimAge associates with lower cognitive ability and brain
vascular lesions in older age, independently of early-life cognitive ability. This epigenetic predictor of mortality associates
with different measures of brain health and may aid in the prediction of age-related cognitive decline.
Introduction
The rapid ageing of the global population has resulted in an
increase in the personal and societal burden of age-associated
disease and disability [1]. Consequently, there is an urgent
need to identify those individuals at high risk of age-related
morbidities and mortality. Recently, a number of methods for
determining biological age have been developed which
leverage inter-individual variation in physiological and
molecular characteristics [2–6]. Primarily, these measures of
biological age have focussed on variation at the level of
DNA methylation (DNAm). DNAm is a commonly-studied
epigenetic mechanism typically characterised by the addition
of a methyl group to a cytosine-phosphate-guanine (CpG)
nucleotide base pairing, thereby permitting regulation of
gene activity [7]. Crucially, these biological age predictors,
also referred to as ‘epigenetic clocks’, correlate strongly with
chronological age; furthermore, for a given chronological
age, an advanced epigenetic age is associated with increased
mortality risk and many age-related morbidities [8–12].
A novel epigenetic clock, termed ‘DNAm GrimAge’ has
been developed to predict mortality [13]. To derive DNAm
GrimAge, an elastic net Cox regression model was used to
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regress time-to-death due to all-cause mortality on chron-
ological age, sex and DNAm-based surrogates for smoking
pack years and 12 plasma proteins. The model selected
chronological age, sex and methylation-based surrogates for
smoking pack years and for 7/12 plasma proteins. The
linear combination of these variables allows for an estima-
tion of DNAm GrimAge. As with other epigenetic clocks, if
an individual’s DNAm GrimAge is higher than their
chronological age, then this provides a measure of accel-
erated biological ageing. Lu et al. [13] comprehensively
demonstrated that an accelerated DNAm GrimAge (also
known as AgeAccelGrim) is associated with a number of
peripheral, lifestyle and cardiometabolic traits and outper-
forms predecessor clocks in predicting death. However, the
relationship between an accelerated GrimAge and cognitive
as well as neuroimaging phenotypes remains unexplored.
As brain structure and cognitive function show mean
declines with age, and associate with disability and disease
burden, the discovery of molecular correlates of neurolo-
gical and neurostructural aberrations may be of particular
benefit in gerontology [14, 15]. In this study we test the
hypothesis that, in a large narrow age-range population
cohort of older adults (Lothian Birth Cohort 1936
(LBC1936)), an accelerated DNAm GrimAge is cross-
sectionally associated with poorer cognitive performance,
structural neuroimaging measures and neurology-related
proteins.
In addition, higher childhood intelligence (as defined by
age 11 IQ) is associated with a lower risk of mortality across
the life course [16–18]. Furthermore, childhood intelligence
associates with a healthier lifestyle and less morbidity in
middle age, as well as a lower allostatic load in older age
[19–21]. Intelligence in early life is related to variability in
cortical thickness, white matter macro- and micro-structure,
as well as cognitive ability, fewer vascular lesions and lower
risk of stroke in later life [22–27]. Notably, adjustment for
age 11 IQ was recently shown to attenuate associations
between another epigenetic clock measure, DNAm Pheno-
Age, and a wide range of phenotypes including cognitive
traits in LBC1936 [28]. Therefore, we also test the
hypothesis that controlling for childhood intelligence
attenuates associations between DNAm GrimAge and mor-
tality, cognitive and neuroimaging measures, as well as
neurology-related proteins in older age.
Materials and methods
The Lothian Birth Cohort 1936
The LBC1936 comprises Scottish individuals born in 1936,
most of whom took part in the Scottish Mental Survey 1947
at age 11. Participants who were living within Edinburgh
and the Lothians were re-contacted ~60 years later. Of these
participants, 1091 consented and joined the LBC1936.
Upon recruitment, participants were ~70 years of age (mean
age: 69.6 ± 0.8 years) and subsequently attended four
additional waves of clinical examinations about every 3
years. Detailed genetic, epigenetic, physical, psychosocial,
cognitive, neuroimaging, health and lifestyle data are
available for members of the LBC1936. Recruitment and
testing of the LBC1936 have been described previously
[29, 30].
Methylation preparation in the Lothian Birth Cohort
1936
DNA from whole blood was assessed using the Illumina
450 K methylation array at the Edinburgh Clinical Research
Facility. Details of quality control procedures have been
described elsewhere (see Supplementary Methods) [31, 32].
Derivation of DNAm GrimAge
DNAm GrimAge was calculated using the online age cal-
culator (https://dnamage.genetics.ucla.edu/) developed by
Horvath [33]. LBC1936 methylation data were used as
input for the algorithm and data underwent a further round
of normalisation by the age calculator. The DNAm
GrimAge biomarker was calculated using a method
developed by Lu et al. [13] and is based on a linear com-
bination of age, sex, DNAm-based surrogates for smoking,
and seven proteins (adrenomedulin (DNAm ADM), beta-2-
microglobulin (DNAm B2M), cystatin C (DNAm cystatin
C), growth differentiation factor 15 (DNAM GDF15),
leptin (DNAm leptin), plasminogen activation inhibitor
1 (DNAm PAI1), and tissue inhibitor metalloproteinaise
(DNAm TIMP1)). Supplementary Fig. 1 shows the corre-
lation between all methylation-based surrogates. All pre-
dictors, with the exception of DNAm Leptin (r2=−0.29),
were positively correlated with DNAm GrimAge (absolute
range= [0.24: 0.82], median= 0.25 and mean of correla-
tion coefficients= 0.25). The difference between DNAm
GrimAge and chronological age (an accelerated DNAm
GrimAge) provides a measure of biological ageing. In a
previous study, for a given chronological age, individuals
with higher DNAm GrimAge had a higher risk for mor-
tality than individuals of the same chronological age with a
lower DNAm GrimAge [13].
Phenotypic data
Our phenotypic analyses were divided into four sections.
Firstly, we examined the association between age-adjusted
DNAm GrimAge and mortality in the LBC1936 over
9 years of follow-up. For our survival models (and later
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longitudinal cognitive analyses), we aimed to determine
whether DNAm GrimAge at Wave 1 of the LBC1936 study
(n= 906; age: 70 years) could predict mortality (or cogni-
tive decline) over all four waves of available data (to age
79 years). For all other phenotypic analyses, we examined
cross-sectional associations with age-adjusted DNAm
GrimAge at Wave 2 (age: 73 years). This is because com-
plete proteomic, brain imaging, DNAm and phenotypic data
were available at this time point only (n= 709 individuals).
For cross-sectional analyses, we did not wish to determine
whether Wave 1 (age: 70 years) epigenetic data associated
with Wave 2 (age: 73 years) phenotypic data in order to
limit the potential issue of retrocausality. In this first sec-
tion, we also investigated the cross-sectional association of
an accelerated DNAm GrimAge with a number of physical
(body mass index, height, grip strength, lung function and
weight) and blood traits (albumin, C-reactive protein, cho-
lesterol, creatinine, ferritin, interleukin-6 and iron; at Wave
2; age 73 years) that have been related to mortality and
frailty in older age [34–42].
Secondly, we tested the association between an acceler-
ated DNAm GrimAge and cognitive traits (n= 18 pheno-
types). Cognitive tests taken at Wave 2 (age: 73 years)
included six Wechsler Adult Intelligence Scale-III UK
(WAIS-III) non-verbal subtests (matrix reasoning, letter
number sequencing, block design, symbol search, digit
symbol, and digit span backward). Principal component
analysis (PCA) was performed using these cognitive tests
and scores on the first un-rotated principal component
(general cognitive ability, g) were extracted which
explained 51% of variance. Individual test loadings ranged
from 0.65 to 0.75. Wechsler Memory Scale-III items as well
as measures of crystallised intelligence and reaction time
were also examined in relation to DNAm GrimAge. In
addition, we examined whether an accelerated DNAm
GrimAge associated with APOE ε4 carrier status. Similar to
our survival analyses, we used Wave 1 epigenetic data to
determine whether DNAm GrimAge (at age 70 years) could
predict decline in general cognitive ability across all four
waves of the LBC1936 study. For this analysis, we used the
lmerTest package in R to fit mixed-effects models to regress
general cognitive ability onto sex and an interaction term
between DNAm GrimAge at Wave 1 and chronological
age, all as fixed effects [43]. In addition, participant ID was
fitted as a random effect on the intercept.
Thirdly, we tested the association between an accelerated
DNAm GrimAge and neuroimaging phenotypes at Wave 2
(age: 73 years, see Supplementary Methods). The brain
MRI acquisition and processing pipeline has been made
available in an open access protocol paper [44]. Total brain,
normal-appearing white matter, grey matter and white
matter hyperintensity volumes were segmented using
a semi-automated multi-spectral technique [45]. These
volumes were then expressed as a proportion of intracranial
volume (ICV), which controls for the confounding effect of
head size. The resultant ratios were tested for associations
with age-adjusted DNAm GrimAge. Diffusion-tensor ima-
ging-derived measures of fractional anisotropy (FA) and
mean diffusivity (MD) were obtained for participants at
Wave 2 (age: 73 years). Prior to conducting region-specific
analyses, general factors of FA (gFA) and MD (gMD) were
derived by entering the left and right FA and MD values
of each tract separately into a PCA. Scores from the first
un-rotated principal component were extracted and labelled
as gFA (variance explained: 52%, loadings: 0.46–0.95) or
gMD (variance explained: 48%, loadings: 0.47–0.88),
respectively. These general factors reflect common micro-
structural properties across main white matter pathways and
capture the common variance in white matter integrity [46].
Fourthly, we tested the association between an acceler-
ated DNAm GrimAge and the levels of 92 neurological
protein biomarkers (Olink® neurology panel). The neurol-
ogy panel represents proteins with established links to
neuropathology as well as exploratory proteins with roles in
processes including cellular communication and immunol-
ogy. Plasma was extracted from 816 blood samples col-
lected in citrate tubes at mean age 72.5 ± 0.7 years (Wave 2;
Supplementary Methods). Protein levels were transformed
by rank-based inverse normalisation. Normalised protein
levels were regressed onto age-adjusted DNAm GrimAge.
Descriptive statistics for phenotypes are presented in
Supplementary File 1. Data collection protocols have
been described fully previously and are described in Sup-
plementary Note 1 [47].
Statistical analyses
DNAm GrimAge was regressed onto chronological age for
all LBC1936 participants. These residuals were defined as
an accelerated DNAm GrimAge (also known as AgeAc-
celGrim). Linear regression models were used to investigate
relationships between continuous variables and an acceler-
ated DNAm GrimAge, as well as age-adjusted methylation-
based surrogates for smoking pack years and the plasma
proteins that feed into DNAm GrimAge. Logistic regression
was used to test the association between methylation-based
predictors and APOE ε4 carrier status. An accelerated
DNAm GrimAge, age-adjusted DNAm Pack Years or age-
adjusted DNAm plasma protein levels were the independent
variable of interest in each regression model and all vari-
ables were scaled to have a mean of zero and unit variance.
Height and smoking status were included as covariates in
the models for lung function (forced expiratory volume
FEV1; forced vital capacity: FVC; forced expiratory ratio:
FER; and peak expiratory flow: PEF). All models were
adjusted for chronological age and sex. Mixed-effects
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models were used to examine the longitudinal association
between an accelerated DNAm GrimAge and general cog-
nitive ability. To investigate possible statistical confounding
by childhood cognitive ability, all models were repeated
with adjustment for age 11 IQ scores. To correct for mul-
tiple testing, and given that the methylation-based pre-
dictors exhibited a high degree of inter-correlation, we
applied the false discovery rate (FDR; [48]) method to
phenotypic association analyses (n= 137 phenotypes),
separately for each predictor. Associations between age-
adjusted DNAm GrimAge and regional cortical volume
were conducted using the SurfStat toolbox (http://www.ma
th.mcgill.ca/keith/surfstat) for Matrix Laboratory R2018a
(The MathWorks Inc, Natick, MA), using the same cov-
ariates as above and FDR correction for multiple testing.
Results
Cohort characteristics
Details of LBC1936 participant characteristics at Waves 1
and 2 are presented in Supplementary File 1. Briefly, 47.6%
of participants in this study were female. At Wave 1
(relating to the mortality and longitudinal analyses), mean
chronological age for both males and females was 69.6
years (SD 0.8), whereas the mean DNAm GrimAge was
67.4 years (SD 5.2). At Wave 2 (relating to cross-sectional
analyses), mean chronological age for both males and
females was 72.5 years (SD 0.7), whereas the mean DNAm
GrimAge was 70.0 years (SD 4.9). The lower mean mea-
sure of epigenetic age when compared to chronological age
may reflect overall good health of the cohort. However, the
variance associated with DNAm GrimAge is much higher
than that of chronological age. When calculated across all
four available waves of the LBC1936 study, DNAm
GrimAge exhibits an intra-class correlation coefficient of
0.85. Mean age 11 IQ scores were 100.69 (SD: 15.37).
Notably, lower IQ scores at age 11 (β=−0.11, P= 0.02)
were associated with an accelerated DNAm GrimAge.
Associations between age 11 IQ and tested phenotypes are
presented in Supplementary File 2.
DNAm GrimAge predicts mortality and associates
with frailty factors in the LBC1936
Mortality in LBC1936 participants was assessed in relation
to an accelerated DNAm GrimAge as well as age-adjusted
DNAm-based surrogate markers for plasma protein levels
and smoking pack years. DNAm GrimAge was derived for
906 participants with methylation data (at Wave 1: age
70 years). There were 226 deaths (24.9%) over 9 years of
follow-up.
A higher DNAm GrimAge was significantly associated
with risk of all-cause mortality (Hazard Ratio (HR)= 1.81
per SD increase in DNAm GrimAge, 95% confidence
interval (CI)= [1.58, 2.07], P < 2.0 × 10−16). Furthermore,
higher levels of age-adjusted DNAm Pack Years were
associated with all-cause mortality in the LBC1936 (HR=
1.64 per SD, 95% CI [1.46, 1.86], P= 2.0 × 10−16). In
relation to methylation-based surrogates for plasma protein
levels, six of the seven DNAm protein surrogates (DNAm
ADM, B2M, Cystatin C, GDF15, PAI1 and TIMP1) were
significantly associated with all-cause mortality (see Sup-
plementary File 3; Fig. 1a). Following adjustment for age
11 IQ, there was very little change in the HRs and all of
the predictors remained significant. Indeed, HRs from all
survival models ranged from an attenuation of 2.4% to
an increase of 1.8% following adjustment for childhood
intelligence.
A Kaplan–Meier survival plot for an accelerated DNAm
GrimAge, split into the highest and the lowest quartiles, is
presented in Fig. 1b illustrating the higher mortality risk for
those with a higher DNAm GrimAge. Kaplan–Meier sur-
vival plots for methylation-based surrogates for smoking
pack years and plasma protein levels are presented in
Supplementary Fig. 2.
For the remainder of the results, only those associations
with an FDR-corrected significant P value ( < 0.05) are pre-
sented herein and in Fig. 2. Full results are presented in
Supplementary File 4. In relation to major mortality- and
frailty-associated physical traits in the LBC1936, an accel-
erated DNAm GrimAge was associated with increased levels
of interleukin-6 (β= 0.37, P= 2.3 × 10-18), C-reactive pro-
tein (β= 0.25, P= 2.8 × 10−8), creatinine (β= 0.16, P=
1.1 × 10−4), an increased body mass index (β= 0.16, P=
2.9 × 10−4), triglyceride concentration (β= 0.13, P= 5.0 ×
10−3) and body weight (β= 0.09, P= 0.04) (Fig. 2). The
relationship between accelerated DNAm GrimAge and tri-
glycerides was no longer significant after controlling for
childhood cognitive ability with the effect size decreasing
from 0.13 to 0.09 (32.5% attenuation) (Supplementary
File 4).
An accelerated DNAm GrimAge was negatively asso-
ciated with all four measures of lung function (β= [−0.16
to −0.27], P= [9.4 × 10−7 to 1.7 × 10−16]), iron levels
(β=−0.24, P= 7.2 × 10−7), low-density lipoprotein
cholesterol levels (β=−0.17, P= 1.1 × 10−4), total cho-
lesterol levels (β=−0.13, P= 1.1 × 10−4) and height
(β=−0.08, P= 0.01) (Fig. 2). Only the relationship
between accelerated DNAm GrimAge and height was
non-significant after controlling for childhood intelli-
gence, with the effect size attenuating from −0.08 to
−0.06 (% attenuation: 24.5%) (Supplementary File 4). On
average, associations were attenuated by 2.5% after con-
trolling for age 11 IQ [ranged from: 19.1% increase (total
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Fig. 2 Cross-sectional association between age-adjusted DNAm
GrimAge and cognitive, neuroimaging and physical traits in the
LBC1936. Cognitive: An accelerated DNAm GrimAge was negatively
associated with the general factor of cognitive ability, digit symbol
coding, symbol search and matrix reasoning tasks. DNAm GrimAge
was also associated with an increased mean four choice reaction time.
Neuroimaging: Age-adjusted DNAm GrimAge was negatively asso-
ciated with the ratios of white matter volume, brain volume and grey
matter volume to intracranial volume, and positively associated with
the ratio of volume of white matter hyperintensities to intracranial
volume. Physical: An accelerated DNAm GrimAge was negatively
associated with four measures of lung function: forced expiratory
volume in 1 s, forced vital capacity, forced expiratory ratio and peak
expiratory flow, as well as levels of iron, low-density lipoprotein
cholesterol and total cholesterol. Age-adjusted DNAm GrimAge was
positively associated with weight, levels of creatinine, body mass
index as well as levels of C-reactive protein and interleukin-6.
Horizontal lines indiciate 95% confidence intervals. BMI body mass
index, CRP C-reactive protein, FCRT four choice reaction time, FER
forced expiratory ratio, FEV forced expiratory volume, FVC forced
vital capacity, GM grey matter, ICV intracranial volume, IL6 inter-
leukin-6, LDL low-density lipoprotein, PEF peak expiratory flow, WM
white matter, WHM white matter hyperintensities
Fig. 1 DNAm GrimAge and its component surrogate markers predict
mortality in the LBC1936. a Forest plot showing hazard ratios and
95% confidence intervals (horizontal lines) from Cox proportional
hazard models for DNAm GrimAge and its constituent DNAm sur-
rogate markers in the LBC1936 (n= 906, no. of deaths= 226
following nine years of follow-up). All associations with the excep-
tions of DNAm Leptin were significant. b Kaplan–Meier survival
curve exhibiting the survival probabilities for the top (highest DNAm
GrimAge) and bottom quartiles (lowest DNAm GrimAge) for DNAm
GrimAge in the LBC1936 following 9 years of follow-up
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cholesterol) to 32.5% attenuation (triglycerides)]. All
associations between blood and physical traits and an
accelerated DNAm GrimAge in this study are presented in
Supplementary Fig. 3. Relationships between all pheno-
types tested in this study and age-adjusted DNAm Pack
Years as well as age-adjusted plasma protein levels are
presented in Supplementary File 5. Significant relation-
ships are further detailed in Supplementary Note 2.
DNAm GrimAge associates with lower cognitive
ability in the LBC1936
An accelerated DNAm GrimAge was significantly asso-
ciated with lower measures of general cognitive ability
(g: β=−0.18, P= 8.0 × 10−6; n= 709). Furthermore, an
accelerated DNAm GrimAge was negatively associated with
all six component tests for fluid intelligence from which g
was derived (see Section “Phenotypic data”; β= [−0.11 to
−0.16], P= [0.02 to 2.4 × 10−4]). In addition, an accelerated
DNAm GrimAge was associated with an increased four
choice reaction time mean (β= 0.16, P= 2.9 × 10−4). Lower
IQ scores at age 70 (which correlated 0.70 with age 11 IQ
scores) were associated with age-adjusted DNAm GrimAge
(β=−0.11, P= 0.02). An accelerated DNAm GrimAge
was also negatively associated with the following measures
of crystallised intelligence: the Wechsler Test of Adult
Reading (β=−0.13, P= 4.0 × 10−3) and the National Adult
Reading Test (β=−0.10, P= 0.03).
Following adjustment for age 11 IQ, an accelerated
DNAm GrimAge remained significantly associated with
general cognitive ability (g: β=−0.12, P= 2.0 × 10−3;
33.9% attenuation). Three out of the six tests which con-
stitute the general intelligence factor remained significant
after adjustment for age 11 IQ (digit-symbol coding, symbol
search, and matrix reasoning). Furthermore, the association
between an accelerated DNAm GrimAge and an increased
mean four choice reaction time remained significant fol-
lowing adjustment for age 11 IQ (Fig. 2). On average,
associations between cognitive tasks and an accelerated
DNAm GrimAge were attenuated by 41.1% following con-
trolling for age 11 IQ (ranging from 21.7% attenuation [four
choice reaction time] to 77.4% attenuation [National Adult
Reading Test]). All associations between cognitive traits and
an accelerated DNAm GrimAge in this study are presented
in Supplementary Fig. 4. Finally, an accelerated DNAm
GrimAge was not associated with APOE ε4 carrier status—
the strongest genetic risk factor for Alzheimer’s disease
(odds ratio= 0.96, 95% CI= [0.93, 1.00], P= 0.06).
Accelerated DNAm GrimAge showed a borderline sig-
nificant association with faster cognitive decline (interac-
tion term between an accelerated DNAm GrimAge at Wave
1 and age: β=−0.018, P= 0.05; n= 906). This associa-
tion was attenuated following adjustment for age 11 IQ
(β=−0.015, P= 0.11, % attenuation: 16.7%). Secondly,
restricting the set of individuals to just those incorporated
into our cross-sectional design (n= 709), accelerated
DNAm GrimAge at Wave 1 was significantly associated
with decline in general cognitive ability across the eighth
decade (β=−0.020, P= 0.03; n= 709). After adjusting
for childhood cognitive ability, this association was
attenuated to non-significance (β=−0.017, P= 0.07, %
attenuation: 15%).
DNAm GrimAge is associated with gross
neurostructural differences in the LBC1936
An accelerated DNAm GrimAge was associated with lower
white matter volume (β=−0.28, P= 1.7 × 10−8), total
brain volume (β=−0.25, P= 1.4 × 10−7) and grey matter
volume (β=−0.22, P= 1.3 × 10−5). Furthermore, an
accelerated DNAm GrimAge was associated with an
increased volume of white matter hyperintensities (β=
0.17, P= 1.0 × 10−3) (Fig. 2). All associations remained
significant following adjustment for age 11 IQ (Supple-
mentary File 4). On average, these associations were
attenuated by 6.98% after adjusting for age 11 IQ. All
associations between neuroimaging traits and an accelerated
DNAm GrimAge in this study are presented in Supple-
mentary Fig. 5.
An accelerated DNAm GrimAge was not significantly
associated with general factors of white matter micro-
structural metrics i.e. fractional anisotropy (β=−0.009,
P= 0.89) or mean diffusivity (β=−0.001, P= 0.98), hence
additional regional analyses were not performed. However,
given that DNAm GrimAge was associated with grey matter
volume, we further tested whether there was regional cor-
tical heterogeneity in relation to the DNAm GrimAge-grey
matter association. The negative association between accel-
erated DNAm GrimAge and cortical volume showed a
degree of regional heterogeneity across the cortical surface
(Fig. 3). The strongest magnitudes were evident in lateral
and medial frontal and temporal regions, extending into
motor and somatosensory cortex as well as into the posterior
cingulate and precuneal areas. In contrast, associations in
occipital and inferior lateral and medial frontal regions
were non-significant. When the associations were addition-
ally corrected for age 11 IQ, the magnitude of the effect sizes
at the FDR-significant loci were weakly attenuated
(mean t-value attenuation= 3.36%; Supplementary Fig. 6).
Association of DNAm GrimAge with neurological
protein biomarkers
Forty of the 92 neurology-related Olink® proteins were
significantly associated with an accelerated DNAm
GrimAge at FDR-corrected P < 0.05 (n= 709). These
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proteins explained between 0.73% (β=−0.09, NC-Dase)
to 7.19% (β= 0.30, SKR3) of inter-individual variation in
an accelerated DNAm GrimAge (in a model which was not
adjusted for age and sex; Supplementary File 6). Following
adjustment for age 11 IQ, 36/40 associations (90%)
remained significant. After adjusting for age 11 IQ, asso-
ciations were, on average, attenuated by 3.03%.
Correlation between DNAm GrimAge and DNAm
Pack Years
We observed that DNAm GrimAge and DNAm Pack
Years were highly correlated (correlation coefficient:
0.82) and were cross-sectionally associated with many of
the same variables in our phenotypic analyses (Supple-
mentary File 7). Therefore, we carried out a follow-up
analysis to determine the difference in magnitude between
the effect sizes for DNAm GrimAge or DNAm Pack
Years in relation to phenotypes associated with both
predictors. Prior to adjusting for age 11 IQ, the effect sizes
had a correlation coefficient of 0.88. However, they were,
on average, 16.5% greater for DNAm GrimAge when
compared to DNAm Pack Years. Following adjustment
for age 11 IQ, the correlation coefficient was 0.84, and the
effect sizes were, on average, 23.1% greater for DNAm
GrimAge upon comparison to DNAm Pack Years. A plot
demonstrating the correlation between effect sizes for
DNAm GrimAge and DNAm Pack Years from our cross-
sectional phenotypic analyses is presented in Supple-
mentary Fig. 7.
Sex-specific differences in associations with DNAm
GrimAge
As a sensitivity analysis, we accounted for an interaction
between age-adjusted DNAm GrimAge and sex. Prior to
adjusting for age 11 IQ, there was evidence for a sex-specific
difference only in the relationships between an accelerated
DNAm GrimAge and all four measures of lung function
(FVC: βGrimAge ×males= 0.50, PGrimAge ×males= 5.6 × 10−39;
FEV: βGrimAge ×males= 0.39, PGrimAge ×males= 1.3 × 10−23;
PEF: βGrimAge ×males= 0.17, PGrimAge ×males= 1.2 × 10−4; FER:
βGrimAge ×males=−0.14, PGrimAge ×males= 0.049) (Supplemen-
tary File 8). The same interaction model was also rerun
accounting for age 11 IQ. Three of the lung function tests
(all but FER), as well as reading ability and general cognitive
ability, exhibited significant interactions between sex and
DNAm GrimAge (Supplementary File 9).
Adjustment for educational attainment
In a further sensitivity analysis, we found that an accelerated
DNAm GrimAge was significantly associated with years of
education (β=−0.12, P= 1.7 × 10−3). Models adjusted for
age 11 IQ were rerun with an additional adjustment for years
of education. Of the 57 relationships which remained sig-
nificant after adjusting for age 11 IQ, eight were attenuated to
non-significance when adjusting for education. These inclu-
ded associations with symbol search and weight (β=−0.10
to −0.08, % attenuation= 22.3%; β= 0.09 to 0.05, %
attenuation= 44.4%, respectively) and with six proteins
Fig. 3 Cross-sectional association between age-adjusted DNAm
GrimAge and regional cortical volume in the LBC1936. Left panel: t
values indicate the magnitude of the negative association (values have
been flipped for visualisation purposes). An accelerated DNAm
GrimAge was negatively associated with cortical volume. Right panel:
Corresponding FDR-corrected P values indicate the spatial distribution
of significant associations. FDR false discovery rate
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(THY 1, RGMA, CDH3, TNFRSF21, NEP and TMPRSS5,
mean attenuation: 8.8%) (Supplementary File 10).
Discussion
In this study, we found that a higher-than-expected DNAm
GrimAge strongly predicted mortality and was associated
with a number of mortality- and frailty-associated traits. This
provides the first external replication of the association
between DNAm GrimAge and survival. After controlling for
childhood cognitive ability, we found that an accelerated
DNAm GrimAge was cross-sectionally associated with lower
general cognitive ability as well as slower reaction time speed
and lower scores on processing speed and perceptual orga-
nisation tasks. There was tentative evidence to suggest that an
accelerated DNAm GrimAge measured at age 70 may predict
decline in general cognitive ability up to age 79. Furthermore,
an accelerated DNAm GrimAge was associated with gross
neuroanatomical differences and vascular lesions in older age.
Finally, a number of neurology-related proteins were asso-
ciated with an accelerated DNAm GrimAge.
DNAm GrimAge was developed using mortality as a
reference and consequently supplants its predecessors in
relation to mortality risk prediction. Indeed, in this study, we
observed a hazard ratio of 1.81 per standard deviation
increase in an accelerated DNAm GrimAge, which outper-
forms that of previous epigenetic clocks (Hannum Age HR:
1.22, Horvath Age HR: 1.19; DNAm PhenoAge HR: 1.17; all
applied to LBC1936) [8, 28]. In relation to mortality- and
frailty-associated traits, the strongest association was between
DNAm GrimAge and interleukin-6. Furthermore, DNAm
GrimAge was strongly associated with C-reactive protein
(whose production is stimulated by interleukin-6). Together,
this corroborates evidence for the “inflammaging” theory
which postulates that chronic, low-grade inflammation sig-
nificantly influences biological ageing and decline [49]. An
accelerated DNAm GrimAge was also associated with lower
low-density lipoprotein cholesterol and total cholesterol. In
older age, lower levels of these blood-based factors are also
associated with higher risk of mortality [50]. In addition,
DNAm GrimAge was associated with a higher body mass
index which does not agree with previous findings showing
that an increased body mass index is protective against
mortality risk [39]. However, this may be driven by a strong
association between DNAm Leptin and body mass index.
Indeed, leptin is an adipose tissue-derived hormone which
acts an appetite suppressant, and is strongly correlated with
body mass index and obesity [51, 52].
We observed a significant relationship between higher
childhood intelligence (as well as age 70 IQ) and a lower
DNAm GrimAge in older age. After controlling for child-
hood cognitive ability, associations between DNAm
GrimAge and tests of crystallised intelligence were atte-
nuated to non-significance. This finding is not surprising
given that crystallised intelligence remains stable through-
out adulthood [53], and that the National Adult Reading
Test strongly retrodicts childhood IQ in this sample [54].
However, relationships between DNAm GrimAge and
general cognitive ability, as well as fluid intelligence mea-
sures, remained significant after adjusting for age 11 IQ.
Nevertheless, these associations were attenuated by an
average of 41.4% following adjustment for age 11 IQ.
Therefore, blood-based methylation changes, as captured by
DNAm GrimAge, helps to explain additional variance in
late life cognitive ability and fluid intelligence.
An accelerated DNAm GrimAge was significantly
associated with gross neurostructural differences, including
reductions in total brain, grey matter and white matter
volumes and increases in white matter hyperintensity
volumes. There was also some heterogeneity in the associa-
tions with regional cortical volume, whereby effects were
strongest in frontal and temporal regions. These regions also
exhibit the largest annual decrease in middle and older age
[55], and are most informative for predicting chronological
age (albeit using cortical thickness rather than volume; [56]).
White matter hyperintensities, which associate with DNAm
GrimAge, have also been linked to cortical loss in temporal
and lateral frontal regions [57]. This may indicate that altered
methylation profiles could help explain mechanistic rela-
tionships between neurovascular lesions and cortical atrophy.
However, adjustment for vascular risk factors such as
hypercholesterolaemia, smoking and diabetes is merited in
this context. Furthermore, white matter hyperintensities are
also related to physical disability, processing speed and
cognitive decline [58, 59]. Additionally, the presence of white
matter hyperintensities doubles the risk of dementia, and
triples the risk of stroke, and is associated with clinical out-
comes in stroke [60, 61]. Therefore, DNAm GrimAge may
capture vital aspects of age-related alterations in neuro-
structural integrity and gross brain pathology.
Here, DNAm GrimAge associated with poorer cognitive
ability and neurostructural correlates of dementia. Dementia
encompasses strong psychiatric components and overlaps
with other psychiatric conditions [62]. In addition, there is a
significant genetic or phenotypic overlap between cognitive
ability and psychiatric conditions, such as schizophrenia and
depression [63, 64]. Furthermore, DNAm GrimAge captured
various deleterious aspects of brain health, including altered
brain structure and neurological protein biomarkers, which
relate to psychiatric disorders. Thus, this composite molecular
predictor of mortality should be measured in other large-scale
R. F. Hillary et al.
cohorts with incident and prevalent neurological and neu-
ropsychiatric phenotype data to determine its utility in pre-
dicting clinically-defined disease.
We observed a very strong correlation between DNAm
GrimAge and DNAm Pack Years. Indeed, the associations
between smoking and mortality, cognitive decline and brain
pathology are well-documented [65–67]. However, the
larger effect sizes for DNAm GrimAge suggest that this
composite biomarker is supplemented by the inclusion of
methylation-based surrogates for plasma protein levels. We
identified associations with a number of neurology-related
proteins (n= 40 before adjustment for age 11 IQ; n= 36
after adjustment for age 11 IQ) which may further inform
the risk of mortality and age-related morbidities, particu-
larly in relation to neurological disease. Future studies are
necessary to define the biological relationships between
such proteins and their relevance to age-related pathologies
and cognitive decline.
The use of methylation-based proxies for smoking pack
years and proteomic data is advantageous as methylation-
based predictors are often more accurate than self-reported
phenotypes, and the cost of complex proteomic platforms is
negated [68]. One strength of this study is that rich data
were available across the eighth decade of life, a period in
which risk of cognitive decline and compromised brain
integrity increases significantly. However, LBC1936 com-
prises relatively healthy older adults, complicating the
generalisability of findings to at-risk clinical populations
and broader age ranges.
In conclusion, we demonstrated that an epigenetic pre-
dictor of mortality associates with cognitive ability, cogni-
tive decline and neuroimaging phenotypes in a cohort of
healthy older ageing adults. These associations were largely
independent of another well-known predictor of mortality,
childhood intelligence. Indeed, methylation alterations in
blood, as captured by DNAm GrimAge, could help provide
early indications towards mortality prediction and decline in
brain health.
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